You just read:

Boehringer Ingelheim's Faldaprevir-Based Treatment Regimen Achieved Viral Cure in up to 80 per cent of Patients with Hepatitis C in Phase 3 Pivotal Trial(1)

News provided by

Boehringer Ingelheim

Apr 23, 2013, 18:45 ET